Summit Therapeutics SMMT Business Segments — Net loss
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Summit Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The official record: Summit Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Summit Therapeutics's business segments — net loss.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Summit Therapeutics's business segments — net loss?
- Summit Therapeutics (SMMT) reported business segments — net loss of -$189.42M in Q1 2026.
- How has Summit Therapeutics's business segments — net loss changed year-over-year?
- Summit Therapeutics's business segments — net loss decreased by 201.1% year-over-year, from -$62.91M to -$189.42M.
- What is the long-term trend for Summit Therapeutics's business segments — net loss?
- Over 3 years (2022 to 2025), Summit Therapeutics's business segments — net loss has grown at a 139.3% compound annual growth rate (CAGR), from -$78.78M to -$1.08B.
- What does business segments — net loss mean?
- The total financial loss incurred by the segment after all expenses.
- How do you interpret business segments — net loss?
- A widening loss is typical for companies in heavy R&D phases, but investors monitor this against cash reserves to assess the need for future financing.
- How does business segments — net loss compare across companies?
- Standard metric for all companies; critical for evaluating the financial sustainability of loss-making entities.